Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib

J Natl Compr Canc Netw. 2015 Jan;13(1):9-13; quiz 13. doi: 10.6004/jnccn.2015.0004.

Abstract

The activating BRAF mutation p.V600E has been identified in many cancers, including colon and lung adenocarcinomas, papillary thyroid cancer, malignant melanoma, and hairy cell leukemia (HCL). Malignant melanoma and HCL are of particular interest because of both the high proportion of cases harboring the mutation and the dramatic responses to BRAF inhibitor therapy reported in the literature. This report presents a patient with HCL and malignant melanoma with the BRAF p.V600E mutation, and discusses the successful treatment of both cancers with the BRAF inhibitor dabrafenib.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Imidazoles / pharmacology
  • Imidazoles / therapeutic use*
  • Leukemia, Hairy Cell / diagnosis
  • Leukemia, Hairy Cell / drug therapy*
  • Male
  • Melanoma / diagnosis
  • Melanoma / drug therapy*
  • Mutation
  • Neoplasms, Second Primary*
  • Oximes / pharmacology
  • Oximes / therapeutic use*
  • Positron-Emission Tomography
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Oximes
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins B-raf
  • dabrafenib